Table 3.

Details regarding participants reporting drug-related psychiatric health aspects over the bariatric surgery procedure that, in retrospect, were temporarily associated with a substantial* change in the dose-adjusted drug concentration

Case No	Surgical procedure	Substance	Baseline		Post-surgery			Health consequences related to changed drug concentrations
			Drug dose	Concentration	Day	Drug dose	Concentration
1	GBP	Citalopram	10 mg	137 nmol/L	+252	10 mg	69 nmol/L	Reported increased dose 3–4 weeks before the final sampling because of psychiatric symptoms
					+374	20 mg	158 nmol/L
2	GBP	Citalopram	10 mg	89 nmol/l	+178	10 mg	42 nmol/L	Reported increased dose 2 weeks before the final sampling because of depressive symptoms
					+386	20 mg	90 nmol/L
3	GBP	Mirtazapine	15 mg	96 nmol/L	+68	15 mg	30 nmol/L	Reported that sertraline had been switched to escitalopram after the first post-surgery sampling without beneficial effects, changed back to sertraline
					+368	30 mg	203 nmol/L
		Sertraline	200 mg	130 nmol/L	+68	200 mg	66 nmol/L
					+368	200 mg	78 nmol/L
4	Sleeve	Mirtazapine	30 mg	140 nmol/L	213	30 mg	87 nmol/L	Reported increased dose 2 months before the final sampling because of the psychiatric condition
					393	45 mg	119 nmol/L

GBP gastric bypass

^*Doubled/halved